A healthcare worker holds a vial of the Moderna COVID-19 vaccine at a pop-up vaccination facility operated by SOMOS Community Care during the coronavirus disease (COVID-19) pandemic in New York on January 29, 2021.

Facebook Facebook Logo Log in to Facebook to connect with Mike Segar Reuters

Moderna’s Covid-19 vaccine was more than 90% effective against Covid-19 and more than 95% effective against serious illnesses for up to six months after the second dose, the company said on Tuesday, citing updated data of its Phase 3 clinical trial.

The update brings Moderna one step closer to bottling its vaccine for full US approval. This is a more rigorous verification process to show that the shot is safe and effective for the intended use. With full approval, Moderna can begin marketing the recordings directly to consumers and selling them to individuals and private companies in the United States

The new data includes cases through April 9 and has assessed over 900 cases of Covid-19, including more than 100 severe cases. The vaccine is currently approved by the Food and Drug Administration for emergency use for people aged 18 and over. The authority can revoke the EEA at any time. Moderna only submitted safety data to the EEA for two months. The FDA typically takes six months for full approval.

The company said its results are preliminary. Moderna announced that updated data on effectiveness against asymptomatic infections and antibody persistence will be released later this year.

The new data comes from a study published in the New England Journal of Medicine that showed that antibodies induced by the Moderna vaccine were still present six months after the second dose. It also comes after Pfizer said earlier this month that its vaccine, which uses technology similar to Moderna, was also shown to be highly effective six months after the second dose.

Isaac Bogoch, an infectious disease specialist who served on various drug data monitoring and safety boards, described Moderna’s update as “amazing news.” It’s great to hear that both mRNA vaccines are highly effective after six months.

“I think it’s fair to estimate that both will have decent effectiveness over many months,” he said.

Moderna is currently evaluating its vaccine in children aged 17 and younger.

The company announced Tuesday that its trials for teens 12-17 years of age are now fully enrolled with approximately 3,000 participants in the United States

The test, in which the shot was tested on 6-month-old to 11-year-old children, is currently enrolled. It is expected that 6,750 healthy pediatric participants will be enrolled in the US and Canada. As in Pfizer’s study, children first receive a low dose of the vaccine before gradually moving on to higher doses.